Compare ES & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ES | WST |
|---|---|---|
| Founded | 1927 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.1B | 17.9B |
| IPO Year | 1994 | 2004 |
| Metric | ES | WST |
|---|---|---|
| Price | $68.47 | $244.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $71.40 | ★ $319.43 |
| AVG Volume (30 Days) | ★ 2.3M | 790.6K |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | ★ 4.66% | 0.36% |
| EPS Growth | ★ 100.88 | 1.49 |
| EPS | 4.56 | ★ 6.79 |
| Revenue | ★ $13,547,244,000.00 | $2,886,900,000.00 |
| Revenue This Year | $2.66 | $6.76 |
| Revenue Next Year | $3.53 | $6.15 |
| P/E Ratio | ★ $14.79 | $35.86 |
| Revenue Growth | ★ 13.83 | 1.95 |
| 52 Week Low | $52.28 | $187.43 |
| 52 Week High | $76.41 | $322.34 |
| Indicator | ES | WST |
|---|---|---|
| Relative Strength Index (RSI) | 40.91 | 51.48 |
| Support Level | $65.56 | $239.86 |
| Resistance Level | $68.84 | $251.73 |
| Average True Range (ATR) | 1.74 | 6.47 |
| MACD | -0.55 | 1.03 |
| Stochastic Oscillator | 27.39 | 65.68 |
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric, gas, and water distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. The company exited most of its unregulated businesses in 2006.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.